UNSPSC 51291707: Isamoltan

This classification denotes an anxiolytic with the molecular formula C16H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2TP37O5J17, chemically known as 2-propanol, 1-((1-methylethyl)amino)-3-(2-(1h-pyrrol-1-yl)phenoxy)- but generally known as isamoltan, which bears US NIH Compound Identifier 127404. European Medicines Agency schedules Isamoltan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08304MIG.

UNSPSC 51291707 Isamoltan, a Commodity code, does not appear to represent the pharmaceutical and naloxone products actually being procured in the recent state and local solicitations tagged under it. The source shows three recent opportunities—two explicitly for naloxone and drug deactivation systems, and a third for generic pharmaceuticals and OTC products through a cooperative purchasing vehicle—but "Isamoltan" does not match the scope of these purchases and appears to be either a data error or a misclassification. The available solicitation records suggest state and local governments are buying naloxone units and drug deactivation systems for community health initiatives, generic pharmaceuticals and OTC products through multistate cooperative agreements, and exploring direct-to-manufacturer prescription programs to streamline pharmacy benefit delivery. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity spans Florida and Texas, with broader multistate participation through MMCAP covering Oregon and other member jurisdictions. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the deadline date appears mismatched to the posting date and should be verified). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. Because the code name does not align with the actual procurement scope documented in the opportunities, confidence in this classification is low and warrants clarification with the issuing bodies or cooperative organization before pursuing opportunities under this code designation.